ATE205537T1 - Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier - Google Patents

Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier

Info

Publication number
ATE205537T1
ATE205537T1 AT97400796T AT97400796T ATE205537T1 AT E205537 T1 ATE205537 T1 AT E205537T1 AT 97400796 T AT97400796 T AT 97400796T AT 97400796 T AT97400796 T AT 97400796T AT E205537 T1 ATE205537 T1 AT E205537T1
Authority
AT
Austria
Prior art keywords
vivo
vaccine
virus
vector
infected
Prior art date
Application number
AT97400796T
Other languages
English (en)
Inventor
David Klatzmann
Jean-Loup Salzmann
Original Assignee
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Curie filed Critical Univ Paris Curie
Application granted granted Critical
Publication of ATE205537T1 publication Critical patent/ATE205537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C17/00—Surface treatment of glass, not in the form of fibres or filaments, by coating
    • C03C17/28—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material
    • C03C17/30—Surface treatment of glass, not in the form of fibres or filaments, by coating with organic material with silicon-containing compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D4/00—Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond ; Coating compositions, based on monomers of macromolecular compounds of groups C09D183/00 - C09D183/16
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
AT97400796T 1996-04-05 1997-04-07 Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier ATE205537T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9604370A FR2747046B1 (fr) 1996-04-05 1996-04-05 Nouveaux vaccins issus de plasmovirus
US09/166,147 US6140114A (en) 1996-04-05 1998-10-05 Defective viral vaccine particles obtained in vivo or ex vivo

Publications (1)

Publication Number Publication Date
ATE205537T1 true ATE205537T1 (de) 2001-09-15

Family

ID=26232637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97400796T ATE205537T1 (de) 1996-04-05 1997-04-07 Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier

Country Status (10)

Country Link
US (1) US6140114A (de)
EP (2) EP1138773A2 (de)
JP (1) JP2000508893A (de)
AT (1) ATE205537T1 (de)
AU (1) AU2394297A (de)
CA (1) CA2251027C (de)
DE (1) DE69706593T2 (de)
ES (1) ES2164309T3 (de)
FR (1) FR2747046B1 (de)
WO (1) WO1997038118A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003832B1 (ru) * 1997-09-15 2003-10-30 Дженетик Иммьюнити, Ллс. Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования
AU1087299A (en) * 1997-10-14 1999-05-03 Avant Immunotherapeutics, Inc. Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens
EP1141338A4 (de) * 1998-12-31 2002-09-25 Arch Dev Corp Rekombinantes herpes simplex virus zur behandlung von neoplastischen erkrankungen
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
AU2002211948B2 (en) 2000-03-02 2007-09-13 Emory University DNA expression vectors and methods of use
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
JP2004535151A (ja) * 2000-10-10 2004-11-25 インスティトゥート フューア ヴィロロギー タイルレヒツフェヒゲス インスティトゥート アン デア ヴェテリネーアメディツィニーシェン ウニヴェルズィテート ヴィーン ウイルス性成分の活性および／または特異性の評価に対する新システム
EP1201750A1 (de) * 2000-10-26 2002-05-02 Genopoietic Synthetische Viren und ihre Verwendungen
WO2002079396A2 (en) * 2001-02-13 2002-10-10 Mosca Joseph D Biological carriers for induction of immune responses
CA2537953A1 (en) * 2003-09-09 2005-03-17 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to hiv in humans
AU2005249450A1 (en) 2004-05-27 2005-12-15 Centocor, Inc. Cynomolgus prostate specific antigen
AU2005329405A1 (en) * 2004-06-15 2006-09-28 Centocor, Inc. Method for screening agents against human prostate disease
ATE511848T1 (de) * 2004-08-25 2011-06-15 Us Gov Health & Human Serv Lebendige mikrobielle mikrobizide
EP1885186B1 (de) * 2005-06-01 2015-09-02 California Institute Of Technology Verfahren zur gezielten genabgabe über virale vektoren
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
AU2007275010B2 (en) * 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
WO2008102368A1 (en) * 2007-02-21 2008-08-28 Rajesh Shah Medicinal formulation containing a combination of hiv type i and hiv type ii
HRP20140327T4 (hr) 2009-07-24 2017-11-03 Immune Design Corp Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
JP2015512263A (ja) 2012-03-30 2015-04-27 イミューン デザイン コーポレイション Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US11091775B2 (en) 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0487587A1 (de) * 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
ATE228569T1 (de) * 1992-02-28 2002-12-15 Syngenix Ltd Defekte verpackende nicht-oncoviren vektoren aus mpmv
JPH08500005A (ja) * 1992-03-27 1996-01-09 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 非感染性ｈｉｖ粒子およびその用途
EP0611822B1 (de) * 1993-02-17 2002-05-22 Wisconsin Alumni Research Foundation Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU2194895A (en) * 1994-03-25 1995-10-17 Uab Research Foundation, The Composition and methods for creating syngeneic recombinant virus-producing cells
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
AT402898B (de) * 1994-08-08 1997-09-25 Int Centre Genetic Eng & Bio Molekulares präsentiersystem
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU716219B2 (en) * 1995-02-24 2000-02-24 Clipmate Corp. Electric detonator and lead connector assembly

Also Published As

Publication number Publication date
DE69706593T2 (de) 2002-07-11
EP0799893A1 (de) 1997-10-08
DE69706593D1 (de) 2001-10-18
FR2747046A1 (fr) 1997-10-10
WO1997038118A1 (fr) 1997-10-16
AU2394297A (en) 1997-10-29
ES2164309T3 (es) 2002-02-16
EP0799893B1 (de) 2001-09-12
CA2251027A1 (fr) 1997-10-16
JP2000508893A (ja) 2000-07-18
CA2251027C (fr) 2009-11-10
US6140114A (en) 2000-10-31
EP1138773A2 (de) 2001-10-04
FR2747046B1 (fr) 1998-06-19

Similar Documents

Publication Publication Date Title
ATE205537T1 (de) Verwendung von plasmiden zur herstellung eines impfstoffs bei mensch und tier
DK0742834T4 (da) Fremgangsmåde til fremstilling af en virusvektor på mindst 20 kb ved intermolekylær homolog rekombination i en prokaryot celle
CA2596274A1 (en) Recombinant mva virus, and the use thereof
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
CY1120209T1 (el) Αλληλουχιες αδενο-εξαρτωμενου ιου (aav) οροτυπου 9, φορεις που τον περιεχουν και χρησεις αυτων
EP1683858A3 (de) Virale Zubereitungen, Vektoren, Immunogene und Impfstoffe
ATE419368T1 (de) System zum transfer und zur expression von heterologen genen ins knochenmark in vivo
NL300313I1 (nl) Vaccin tegen humaan papillomavirus
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
EP1923467A3 (de) Adenovirusvektoren für die Gentherapie
RU2003118436A (ru) Модифицированный вариант вируса коровьей оспы ankara
RU98101904A (ru) Рекомбинантный вирус mva и его использование
CA2290696A1 (en) Immunopotentiating composition
JPS6349077A (ja) ベクターウイルスおよびベクターウイルスを含む薬用組成物
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
CN109536529A (zh) 一种高效重组痘苗病毒载体及其建立方法
EP2145961A3 (de) Adenovirus-Typ-3-Genom des Schweins
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE237629T1 (de) Rekombinanter virus der marek-krankheit, verfahren zur herstellung dieses viruses und diesen enthaltender impfstoff
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
CN1094974C (zh) 表达人白细胞介素12的重组腺病毒及其制法和用途
DK257887D0 (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
CN109837245A (zh) 一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用
ATE332920T1 (de) Nukleinsäureimpfstoff bestehend aus einem fusionsprotein, dass eine adjuvanssequenz von einem planzenvirushüllprotein aufweist

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee